

Express Scrips Pharmacy Management Fund & Advanced Opioid Management Program

November 18, 2019




## Agenda

- Pharmacy Management Fund
  - Permitted Uses
  - Available Funding
- Opioid Prescribing & Risk in State Group Health Plan
- Advanced Opioid Management Program
  - Purpose and objective
  - Added benefits
- Recommendation and Effective Date

## Pharmacy Management Fund (PMF)

- Approved uses include clinical program fees and custom communications, IT development for client specific projects and custom data file extracts.
- Provides an allowance of \$5.00 per covered life
- Current balance including prior contract carryover is \$800,000

## State Group Health Plan Opioid Prescribing & Risk



potential costs avoided from detrimental outcomes due to the misuse and abuse of opioids. The estimates were created using peer-reviewed literature and government agency information and employing the standards of critical review outlined and supported by the U.S. Preventative Services Task Force, differentiating quality research into good, fair, and poor. Therefore, the estimates were based on the best available studies as of May 16, 2017.

Epidemic costing employers \$18 billion; contributing to 64% of medically-related absenteeism


Source: The Opioid Crisis Report, www.castlighthealth.com

201908-31

## Express Scripts Existing Opioid Management

- Today, Express Scripts provides enhanced Fraud, Waste and Abuse services
  - Using analytics and data mining identifies outliers
  - Investigates and performs prescription verification, prescriber outreach and collaborates with SBO regarding intervention opportunities
  - Approach identifies abuse AFTER member is prescribed opioids

## Advanced Opioid Management Program



\*Effective 9/1/2019 <sup>1</sup>Enhanced Fraud, Waste & Abuse <sup>2</sup>New users only, existing users limited to >200MME

on higher-than-therapeutic doses

## Pharmacy Management Fund (PMF) Recommendation

- Adoption of the Advanced Opioid Management Program (estimated start dates)
  - 3/1/20 6/30/21 Commercial
  - 3/1/20 12/31/21 EGWP
  - Estimated cost \$775k
- Expand permitted uses of Pharmacy Management Funds in CY2020 Prescription Benefit RFP
- Evaluate effectiveness/cost of Opioid Management Program; negotiate program and fees in CY2020 Prescription RFP/new contract

Note: Remaining balance of PMF will be used for previously approved IT/data projects



## Thank You



Phone: 1-800-489-8933 Email: <u>benefits@delaware.gov</u> Website: <u>de.gov/statewidebenefits</u>

## Appendix



## Opioids and Adjacent Therapy Still a Problem

#### What the Nation is Facing:

people died every day in 2017 from a drug overdose involving an opioid<sup>2</sup>

*increase in ER visits in the U.S. from* 2016 to 2017<sup>2</sup>

Opioid-adjacent therapies multiply risks—enhancing opioid-related highs and many are addictive in and of themselves.

 $\mathcal{P}_{\mathcal{O}}$ 

ታ



30%

130

opioid-related deaths involve a benzodiazepine<sup>2</sup>

Costing employers \$18 billion & contributing to 64% of medicallyrelated absenteeism.<sup>3</sup>

<sup>2</sup>Centers for Disease Control and Prevention <sup>3</sup>The Opioid Crisis Report, www.castlighthealth.com



## Education, Proactive Care and Safe Disposal

#### **Enabling Members at Home**

#### Addressing a big gap: your patients are NOT aware of opioid risks

- **1.** Educational letter at first fill for new and more chronic users
- 2. Proactive outreach from our specially trained Neuroscience Therapeutic Resource Center<sup>SM</sup> (TRC) pharmacists A TRC neuroscience pharmacist contacts each opioid naïve patient and those on the verge of chronic use
  - ✓ Now supporting members in the recovery part of the spectrum with outbound calls to members on Medication-assisted treatment (MAT)\*
- **3.** Provide safe deactivation drug disposal bags for opioid and certain opioid potentiator prescriptions
- **4.** Bringing additional awareness to patients by providing suicide, mental health and addiction hotline resources for members needing someone to talk to on select member-facing materials<sup>\*</sup>

# **50%**

of patients were abstinent from opioids 18 months after starting therapy <sup>2</sup>

\*Effective 9/1/19 <sup>1</sup>Centers for Disease Control and Prevention <sup>2</sup>National Institute for Drug Abuse



## Influence Needed at Point of Care

#### **Enabling Prescribers**

Duplicate therapy, drug-drug interactions and adverse drug reactions
 Misuse and abuse, including multiple prescribers and pharmacies
 Exceeds morphine equivalent dose threshold
 Gaps in care, including recommending naloxone
 Identifying vulnerable populations taking opioids
 Poor adherence to opioid use disorder medication

Prescriber education & peer comparison

- Identifying patients seeking multiple prescribers for opioids
- Peer comparison letters to opioid prescribers who are outliers
- CDC prescribing recommendations

(O) (C) (C)

Every day, we enable prescribers at the pointof-care with integrated patient data and safety alerts delivered right through their EHR.<sup>1</sup>



<sup>1</sup>Electronic Health Record. If prescriber is not connected, alert will be sent by fax. If secure fax is not available, alert will be sent by letter



## Safety Interventions at Point of Sale

#### **Enabling Pharmacies**

Initial fill days' supply	<ul> <li>Adults initiating opioid therapy are limited to a 7-day supply; effective 9/1/19, limit for each of their first 4 fills*</li> <li>✓ 3-days' supply for individuals under 18, limit for each of their first 4 fills*</li> </ul>
MME edit >200MME (90MME <sup>*1</sup> )	Daily threshold level of morphine equivalent dose accumulating across all opioid claims
Fentanyl specific rules	Tightening criteria for fentanyl products & new drug quantity management (DQM) for patches
Long-acting opioid PA	Stops long-acting opioid prescription without a long-acting opioid in member's claim history
Adjacent therapies	Quantity limits of opioid adjacent therapies: commonly-abused benzodiazepines, gabapentin & certain muscle relaxants

93%

of patients enrolled in our program prescribed an opioid for the first time, started with a 7-day supply or less.<sup>2</sup>

\*Effective 9/1/19 <sup>1</sup>New users only, existing users limited to >200MME <sup>2</sup>One year program results



## Enhanced FWA Auto Lock Management


Helping patients find 1 prescriber & 1 pharmacy for a home base and forced coordinated care



2,200+ substantiated cases were presented to plans in 2018 resulting in avoidance of up to \$62M in related prescription costs and \$2.5B in related medical costs<sup>1</sup>



Prior to auto-lock management, a member had obtained 43 controlled substance Rxs from 17 prescribers and 5 pharmacies—with forced coordinated care, our client saved more than \$40,000 for just that one member alone<sup>1</sup>



<sup>1</sup>Express Scripts Enhanced, Fraud, Waste & Abuse program results

## **Program Costs**

Commercial Fee - \$0.39 PMPM

EGWP Fee - \$0.26 PMPM

\$469K Annually \$81K Annually \*Total Annual Cost \$550k (\$45k/Month)

Commercial Rebate Loss - \$70K EGWP Rebate Loss - \$0.00